| Literature DB >> 23717168 |
Abstract
Actoprotectors are preparations that increase the mental performance and enhance body stability against physical loads without increasing oxygen consumption. Actoprotectors are regarded as a subclass of adaptogens that hold a significant capacity to increase physical performance. The focus of this article is studying adaptogen herbs of genus Panax (P. ginseng in particular) and their capabilities as actoprotectors. Some animal experiments and human studies about actoprotective properties of genus Panax attest that P. ginseng (administered as an extract) significantly increased the physical and intellectual work capacities, and the data provided suggests that ginseng is a natural source of actoprotectors. Preparations of ginseng can be regarded as potential actoprotectors which give way to further research of its influence on physical and mental work capacity, endurance and restoration after exhaustive physical loads while compared with reference actoprotectors.Entities:
Keywords: Actoprotector; Ginseng; Memory; Panax ginseng; Physical work capacity
Year: 2013 PMID: 23717168 PMCID: PMC3659633 DOI: 10.5142/jgr.2013.37.144
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Fig. 1.Structures of actoprotectors. (A) Bemitil, (B) ethomersol, (C) bromantane, and (D) chlodantane.
Fig. 2.Influence of benzimidazole actoprotector (50 mg/kg) on duration of repeated running (% of first running) (A), content of glycogen in liver (B), and total RNA content in liver (C) of rats during recovery after running. 1, initiative parameter (for work capacity) or parameter of intact group (for content of glycogen and RNA); 2, control group; 3, experimental group (actoprotector administration). *p<0.05 in comparison with duration of repeated running of rats from control group [36].
Fig. 3.Chemical structure of ginsenosides. (A) Protopanaxadiol-type ginsenoside, (B) protopanaxatriol-type ginsenoside. glc, b-D-glucopyranosyl; arap, a-L-arabinoyranosyl; araf, a-L-arabinofuranosyl; Ac, acetyl; Ma, malonyl; rha, a-L-rhamnopyranosyl.
Results of human studies with plants from genus Panax on physical performance (adapted with modifications from [67])
| Study (reference) | Subject (n) | Study design | Subject age range | Daily dose | Preparation type | Study duration | Effects (statistically significant unless otherwise stated) |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Dorling et al., 1980 (cited in | 60 | DB, PC | 22-80 yr | # | G115 | 12 wk | Improved visual and auditory reaction times, postexercise recovery (stair climbing), 2-handcoordination, alertness, and subjective assessments |
| Forgo et al., 1981 (cited in | 20 | NC | 18-31 yr | 200 mg | G115 | 9 wk | Increased aerobic capacity; reduced lactate production, and heart rate |
| Forgo et al., 1981 | 120 | DB | 30-60 yr | 200 mg | G115 | 12 wk | Improved vital capacity, forced expiration volume, maximum expiratory flow, maximal breathing capacity, work output; NS for serum LH, FSH, testosterone, estradiol, blood chemistries |
| Forgo et al., 1982 (cited in | 30 | NC | Elite young athletes | 200 mg | Standardized extract, 4% or 7% ginsenoside content | 9 wk | Improved aerobic capacity; reduced lactate production, and heart rate; NS for difference between 4% and 7% ginsenoside content |
| Forgo, 1983 | 30 Elite athletes | DB, PC | 19-31 yr | 200 mg | G115 | 9 wk | Improved oxygen uptake, maximal breathing capacity, vital capacity, and forced expiration volume; reduced lactate production ,and heart rate; NS for serum LH, testosterone, and cortisol |
| Knapik et al., 1983 (cited in | 11 Marathon runners | DB, PC | # | 2,000 mg | 1.5% glycosides | 4 wk | NS for R values, glucose, lactate, free fatty acids, glycerol, insulin, cortisol, and growth hormone |
| Teves et al., 1983 (cited in | 12 Marathon runners | DB, PC | 22±1 yr | 2,000 mg | 1.5% glycosides | 4 wk | NS for run time to exhaustion, aerobic capacity, heart rate, VE, and RPE |
| Murano et al., 1984 (cited in | 65 | NC | 18-21, 38-70 yr | 2 capsules for 30 d,1 capsule for 30 d | ARM229 standardized extract | 60 d | Older group: improved performance in Cooper test (12-min run time); younger group: NS trend in Cooper and Harvard step tests |
| Forgo et al., 1985 (cited in | 28 Elite athletes | DB, PC | 20-30 yr | 200 mg | G115 | 9 wk | Improved oxygen uptake, forced expiration volume, vital capacity, visual reaction times, and heart rates |
| Ng et al., 1986 (cited in | 214 | # | # | # | # | # | Improved endurance, maximal oxygen uptake, postexercise recovery, simple reaction time |
| Macareg et al., 1986 (cited in | 12 | R, DB,PC, CO | # | # | # | # | NS for time to exhaustion, glucose, and lactate |
| Von Ardenne et al., 1987 | 10 | NC | 50 yr | 200 mg | G115 | 4 wk | Improved resting PO2 uptake (arteriovenous difference) by 29% |
| Tesch et al., 1987 (cited in | 38 | PC | 50-54 yr | 80 mg | Standardized extract, vitamins, minerals | 8 wk | Improved heart rate and lactate production (> 180 W), RPE (60, 80, 120 W workloads); NS for lactate production up to 180 W |
| McNaughton et al., 1989 (cited in | 15 F, 15 M | R, DB, PC, CO | # | 1,000 mg | Ginseng root powder | 6 wk | Improved aerobic capacity, pectoral strength (27%), quadriceps strength (18%), postexercise recovery; NS for grip strength |
| Gribaudo et al., 1990 (cited in | 12 M | R, DB, PC, CO | Young | 1,000 mg | Ginseng + fenu greek | 15 d | Improved total work output, NS for lactate |
| Gribaudo et al., 1991 (cited in | 14 Well trained amateur cyclists | R, DB, CO | # | 1,000 mg | Ginseng + fenu greek | 30 d | Improved maximal work, VO2 max, anaerobic threshold, NS for lactate |
| Pieralisi et al., 1991 | 50 | R, DB, PC, CO | 21-47 yr | 200 mg | Standardized extract plus DMAE, vitamins, minerals | 6 wk | Improved total work load, time to exhaustion, aerobic capacity, ventilation, oxygen consumption, carbon dioxide production, lactate production, and heart rate; NS for RER |
| Van Schepdael 1993 (cited in | 43 F triathletes | R, DB, PC, CO | 24-36 yr | 400 mg | G115 | 20 wk | Prevented loss of physical fitness after 10 wk |
| Engels et al., 1995 (cited in | 19 F | DB | 26±1 yr | 200 mg | G115 | 8 wk | NS for exercise recovery (heart rate, lactate production, oxygen consumption, and ventilation) |
| Caso Marasco et al., 1996 | 625 | R, DB, PC | 18-65 yr | 200 mg | Standardized extract plus minerals, vitamins | 12 wk | Improved quality of life, prevention of increased body weight and high blood pressure |
| Engels et al., 1997 | 36 M | R, DB, PC | # | 200 or 400 mg | G115 | 8 wk | NS for oxygen consumption, RER, RPE, lactate, and heart rate during exercise |
| Lifton et al., 1997 | 7 M, 4 F well trained | DB, CO | # | 3 g | # | 13 d | NS for heart rate max, VO2 max, total workload |
| Allen et al., 1998 | 8 F, 20 M | R, DB, PC, CO | 23±3 yr | 200 mg | 7% ginsenoside standardized extract | 3 wk | NS for oxygen uptake, exercise time, workload, lactate production, hematocrit, heart rate, ratings of perceived exertion at150 W, 200 W, or peak |
| Kolokouri et al., 1999 | 24 F | DB, PC | Adult | 400 mg | # | 8 wk | NS for peak anaerobic power output, fatigue reate |
| Ziemba et al., 1999 | 15 Soccer players | DB | 19.07±0.62 yr | 350 mg | Ginseng preparation | 6 wk | Improved psychomotor performance during bicycle ergometer exercise without affecting exercise capacity |
| Engels et al., 2001 | 24 F | DB | # | 400 mg | G115 | 8 wk | No ergogenic benefits during and in the recovery from short, supramaximal exercise |
| Cardinal et al., 2001 | 83 Adults (40 F, 43 M) | R, DB, PC, CO | Mean age, 25.7 | 200 or 400 mg | G115 | 8 wk | No evidence that chronic ginseng supplementation enhancing affect or mood in healthy young adults |
| Kang et al., 2002 | 8 College students | R, PC | Young | 20 g | Ginseng root extract | Acute administration, after exercise | NS after and during 2 h recovery period for cortisol, testosterone, hGH, insulin-like growth factor |
| Kim et al., 2005 | 7 M | # | # | 6 g | Standardized extract | 8 wk | Ginseng supplementation has ergogenic properties in facilitating recovery from exhaustive exercise |
| Engels et al., 2003 | 27 | R, DB, PC | # | 400 mg | G115 | 8 wk | No changes in secretory IgA at rest and after an exercise induced state of homeostatic disturbance. No evidence for improvement of physical performance and heart rate recovery of individuals undergoing repeated bouts of exhausting exercise |
| Kulaputana et al., 2007 | 60 M | # | 17-22 yr | 3 g | 100% ginseng | 8 wk | No changes of lactate threshold and physical performances in physically active men |
| Ping et al., 2011 | 9 Heat adapted recreational runners | R, DB, PC | 25.4±6.9 yr | 200 mg | # | Acute administration, 1 h before running | No influence on the endurance running performance of the heat-adapted male recreational runners in the heat |
| Jung et al., 2011 | 18 M | # | Young | 20 g | Korean red ginseng extract | 7 d | Reduced exercise-induced muscle damage and inflammatory responses, resulting in improvements in insulin sensitivity |
| Morris et al., 1996 | 1 F, 7 M | R, DB, PC | 27±5 yr | 8 or 16 mg/kg | Water-ethanol extract | 7 d | NS for cycle time to exhaustion and physiologic responses |
| Biondo et al., 2008 | # | # | # | 1,125 mg | 35 d | No influence on exercise-induced changes in plasma concentrations of lactate, insulin, cortisol, or growth hormone | |
| Liang et al., 2005 | 29 Untrained adults | # | 20-35 yr | 1,350 mg | # | 30 d | Improves endurance time to exhaustion, and lowered mean blood pressure and VO2 during endurance exercise |
#, data not listed or unavailable; CO, crossover; DB, double-blind; DMAE, dimethylaminoethanol; F, female; FSH, follicle stimulating hormone; LH, luteinizing hormone; M, male; NC, not controlled; PANAS, positive and negative affect schedule; PC, placebo-controlled; POMS, profile of mood survey; R, randomized; RER, respiratory exchange ratio; RPE, ratings of perceived exertion; SB, single-blind; VE, expiratory ventilation.
Results of animal experiments with separated ginsenosides and preparations of plants from genus Panax on cognitive functions
| Study (reference) | Preparation type | Animals and experimental model | Daily dose and study duration | Briefly results |
|---|---|---|---|---|
|
| ||||
| Separated ginsenosides | ||||
| Zhang et al., 1990 | Rg1 and Rb1 | Mice, rats; one trial avoidance learning method | # | Rg1 and Rb1 improved acquisition, consolidation and retrieval of memory improved by amnestic agents |
| Benishin et al., 1991 | Rb1 | Rats, scopolamine-induced memory deficit | # | Rb1 partially prevented memory deficits |
| Ma et al., 1993 | 20(S)-ginsenoside-Rg2 | Male Wistar rats, two-way active avoidance method | 20 mg/kg i.p., repeatedly | Positive influence on memory function |
| Li et al., 1999 | Pseudoginsenoside-F11 from | Mice, rats; scopolamine-induced memory deficit | 1-4 mg/kg/d (i.p.), once time or 5 d course | Compound antagonized the memory dysfunction induced by scopolamine |
| Yamazaki et al., 2001 | Panaxynol | Mice, scopolamine-induced memory deficit | 20 mg/kg/d, i.p., for 3 d | Improvement of scopolamine-induced memory deficit |
| Bao et al., 2005 | Rg3(R), Rg3(S) and Rg5/Rk1 (a mixture of Rg5 and Rk1, 1:1, w/w) | Mice, ethanol and scopolamine-induced memory deficit | p.o., course 4 d | Rg3(S) and Rg5/Rk1 significantly reversed the memory dysfunction induced by ethanol or scopolamine |
| Yang et al., 2009 | Rh2 | Mice, scopolamine-induced memory deficit | 40 mg/kg, p.o. 1 h before the first trial session at every consecutive day | Rh2 ameliorated scopolamine-induced learning deficit in mice |
| Wang et al., 2010 | Rg1 and Rb1 | Mice, scopolamine-induced memory deficit | 6 and 12 mg/kg, i.p., 7 d | Multiple administrations of Rg1 and Rb1 are effective in improving memory deficiency induced by scopolamine. Rg1 and Rb1 ameliorated cognition-deficiency in mice with dementia. Rg1 showed stronger effects than Rb1. Both Rg1 and Rb1 increased acetylcholine levels in the hippocampus, but Rg1 inhibited acetylcholinesterase activity while Rb1 had no effect on its activity. Both Rg1 and Rb1 inhibited the decrease of 5-HT induced by scopolamine, but Rb1 was more active than the same dose of Rg1. Rg1 appears to be more potent than Rb1 in improving acquisition impairment. |
| Lasarova et al., 1987 | G115 | Rats, electroconvulsive shock-induced memory disturbances | 30 mg/kg/d (p.o.), 10 d | Tendency for elimination of the memory-impairing effect of electroconvulsive shock. |
| Petkov et al., 1987 | G115 | Rats, “shuttle-box” method for active avoidance | 3, 10, 30, 100 and 300 mg/kg/d (p.o.), 10 d | The results show that ginseng at appropriate doses improves learning, memory and physical capabilities. Bell-shaped dose-effect curves, reported with other nootropic drugs, were obtained. |
| Zhang et al., 1987 | # | Mice | # | Induction of memory facilitation |
| Jaenicke et al., 1991 | # | Female rats of two groups (6 and 27 mo), passive avoidance test | 30 mg/kg/d (p.o.), 13 d | Increasing of learning ability in older rats |
| Petkov et al., 1992 | Standardized extracts: from stem and leaves (GL), and from roots (G115) | Rats with undisturbed memory and in rats with experimentally-impaired memory (electroconvulsive shock); methods for active avoidance (shuttle-box) and passive avoidance (step-down, step-through), the water-maze method and the method for studying exploratory behavior | Multiple administration | G115 exerted favorable effects on learning and memory and on the higher nervous activity as a whole; GL had, in the majority of cases, an effect weaker than that of G115 or was without effect at all |
| Petkov et al., 1993 | G115 | Young (aged 3 months) and old (aged 26 months) rats; conditioned-reflex methods with punishment or positive reinforcement for active and passive avoidance (shuttle-box, step-down, step-through, and water maze) | 17, 50, and 150 mg/kg/d (p.o.), 7 d before training | Positive influence on memory effects, similar to those of nootropic drugs |
| Nitta et al., 1995 | Standardized extract | Aged Fischer 344 rats | 8 g/kg/d, p.o. for 12-33 d | Subchronic treatment with ginseng extract improves spatial cognitive impairment in aged rats |
| Nitta et al., 1995 | Rats; scopolamine-induced disruption of radial maze performance | |||
| Wang et al., 1995 | Root saponins | Normal male Wistar rats | 50 mg/kg/d (ig.), 7 d | Ginseng root saponins facilitate the learning and memory of normal male Wistar rats and significantly raise the levels of biogenic monoamines in their brain |
| Zhao et al., 1998 | Crude ginseng extract | Normal and brain-damaged (sham or medial prefrontal cortex lesions) rats | 40 or 80 mg/kg daily during 30 d after operation | administration of the higher dose resulted in better performance in the learning paradigm |
| Jin et al., 1999 | Root saponins with a low PD/PT (1.24) and high PD/PT (1.46) ratio | Mice, scopolamine-induced memory deficit | 50 and 100 mg/kg (intraperitoneally) before training | The two saponins improved the scopolamine-induced learning impairment at both dosages. The two saponins did not show a favorable effect on learning and memory in normal mice. Korean red ginseng saponin with a low PD/PT ratio had an improving effect on spatial working memory, but the saponin with a high PD/PT ratio did not |
| Hsieh et al., 2000 | # | Rats, scopolamine-induced memory deficit | 1-week course (p.o.) | Improvement of the scopolamine-induced learning and memory deficit |
| Petkov et al., 2003 | G115 | Rats, experimentally-impaired memory (by alcohol or by muscarinic- and dopamine-receptor antagonists) model | # | Favorable effects on learning and memory. These effects varied with the dose and administration schedules, with the rat strain and with the behavioral method |
| Kurimoto et al., 2004 | Nonsaponin fraction of red ginseng | Aged rats | # | Nonsaponin fraction of red ginseng contains important substances to improve learning and memory in aged rats and that this amelioration by nonsaponin might be attributed partly to augmentation of long-term potentiation in the hyppocampal CA3 subfield |
| Lee et al., 2010 | Methanol extracts of wild and cultivated ginseng | Rats; scopolamine-induced memory deficit | 7 days at 30 min before scopolamine injection (2 mg/kg, i.p.) | Wild ginseng demonstrates a significant neuroprotective effect against scopolamine-induced neuronal and cognitive impairment |
| Sanghavi et al., 2011 | Standardized extract | Rats; reserpine-induced orofacial dyskinesia | 100 and 200 mg/kg, p.o., 3 wk | Korean ginseng extract could be useful in the treatment of drug-induced dyskinesia and amnesia |
| Sloley et al., 1999 | Standardized extract (HT-1001) | Sprague-Dawley rats; scopolamine-induced memory deficit | 200 mg/kg/d (p.o.), 8 d | HT-1001 demonstrates a capacity to protect against scopolamine-induced memory deficits (protected against scopolamine-induced amnesia and increased choline uptake in synaptosomal preparations; did not alter brain concentrations of norepinephrine, dopamine, serotonin, 3,4-dihydroxyphenylacetic acid or 5-hydroxyindoleactic acid) |
| Zhong et al., 2000 | Red ginseng powder (Ginseng Radix rubura, Seikansho, Kobe, Japan) | Young (10-12 wk) and aged (28-32 mo) Fisher-344 rats; brain ischemia model | # | Red ginseng ameliorates learning and memory deficits through effects on the central nervous system, partly through effects on the hippocampal formation |
| Wang et al., 2006 | Ginsenisides (containing both protopanaxadiol- and protopanaxtriol-type saponins), isolated from the dry roots of | Male Sprague-Dawley rats (3-4 months old); beta-amyloid-induced amnesia model | 80 mg/kg/d p.o., 5 d before icv beta-amyloid injection and 7 d afterward; or the same dose 12 d but only after β-amyloid injection | Ginsenosides pre-treatment can functionally prevent the beta-amyloid-induced memory loss possibly by minimizing the inhibitory effect of beta-amyloid on hippocampal cholinergic transmission |
| Chatterjee et al., 2012 | Standardized extract | Male Swiss albino mice | 12.5-200 mg/kg, p.o. | |
| Hsieh et al., 2000 | # | Rats, scopolamine-induced memory deficit | 1 week course (p.o.) | Improvement of the scopolamine-induced learning and memory deficit |
| Chuang et al., 2008 | PNB | Rats, cerebral infarct model | 0.5 g/kg/d, p.o., 3 d per week for 4 wk | PNB attenuates impairment of learning and memory functions and increases ED1, BDNF and beta-secretase immunoreactive cells in chronic stage ischemia-reperfusion injured rats |
| Zhong et al., 2011 | PNS | SAMP8 | High and low doses of PNS | PNS can improve the abilities of learning and memory of SAMP8, the mechanism may be relevant to down-regulating the expression of APP gene at transcriptional level |
| Zhang et al., 1987 | # | Mice | # | Induction of memory facilitation |
#, data not listed or unavailable; i.p., intraperitoneal; p.o., per os; WSF, water-soluble fractions; LSF, lipid-soluble fractions; PD, protopanaxadiol; PT, protopanaxatriol; PNB, P. notoginseng Burk; BDNF, brain derivative neurotrophic factor; PNS, P. notoginseng saponins; SAMP8, senescence accelerated mouse prone 8.
Results of human studies with plants from genus Panax on neurocognitive function (adapted with modifications from [67])
| Study (reference) | Subject (n) | Study design | Subject age range | Daily dose | Preparation type | Study duration | Effects (statistically significant unless otherwise stated) |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Kochmareva, 1958 | 122 | CO, PC, SB | Students | 2 mL | Tincture | Acute | Increased quality and quantity of mental work performed |
| Medvedev, 1963 | 13 | CO, PC, SB | 21-23 yr | 2 mL | Tincture | Acute | Decreased errors in data sent by radio operators 1 h after drug uptake |
| Popov et al., 1973 | 32 M | DB, PC | 21-23 yr | 2-mL extract | 40% ethanol tincture | Acute | Decreased errors in radio transmission of coded messages (17% compared with 31%); NS for number of characters transmitted |
| Sandberg, 1974 (cited in | 30 | DB, PC | Students | # | # | # | NS for spiral maze tracing test, letter cancellation test |
| Revers et al., 1976 (cited in | # | DB | Elderly | # | G115 | 90 d | Improved vitality, alertness, rigidity, concentration, visual-motor coordination, positive outlook, visual and auditory reaction times |
| Simon et al., 1977 | 36 | # | Elderly | # | G115 | 90 d | Improved concentration, and mental accuracy; NS for attention |
| Bae, 1978 (cited in | 32 | DB, DC | 21-23 yr | # | # | # | Reduced telegraphy mistakes (17% compared with 31%); NS for mental concentration, coordination |
| Schmidt, 1978 (cited in | 540 | PC | # | # | # | # | Improved subjective and objective indexes; normalized blood glucose and blood pressure |
| Dorling et al., 1980 (cited in | 60 | DB, PC | 22-80 yr | # | G115 | 12 wk | Improved visual and auditory reaction times, hand coordination, alertness, and subjective assessments |
| Sandberg, 1980 (cited in | 60 | DB, PC | # | # | 2 Types of standardized extract | 12 wk | Improved spiral maze tracing test, letter cancellation test, and oxygen metabolism (15-min step test) |
| Johnson, 1980 (cited in | 38 | # | Dental students | # | # | # | NS for mathematics performance, blood cortisol and epinephrines, proofreading error detection, mood, and fatigue indexes |
| Forgo et al., 1981 | 120 | DB | 30-60 yr | 200 mg | G115 | 12 wk | Improved vital capacity, forced expiration volume, maximum expiratory flow, maximal breathing capacity, reaction times, subjective assessments of mood, work output, sleep, concentration, vitality; NS for serum LH, FSH, testosterone, estradiol, blood chemistries |
| Hallstrom et al. 1978 | 12 Nightshift nurses | DB, PC, CO | 21-27 yr | 1200 mg | Korean white ginseng powder | 3 d | Improved tapping rate test; NS for mood, somatic symptoms, blood glucose (all trends); negative effects on sleep quality |
| D’Angelo et al., 1986 | 32 | DB, PC | 20-24 yr | 200 mg | G115 | 12 wk | Improved mental arithmetic calculations; NS trend for attention, choice reaction time, auditory reaction time; NS for tapping test, recognition, and visual reaction time |
| Zhao, 1990 | 481 | # | 50-85 yr | 150 mg | Sugar-coated tablets of GRS | 2 months | GRS possessed antisenility effect and marked effect on relieving the symptoms of aging, adjusting organic metabolism and improving physiological function, etc., such as promoting memory, raising the amount of white cells and improving organic immunity function. |
| Wiklund et al., 1994 | 390 | PC | Middle-age | 200 mg | G115 + vitamins, minerals | 12 wk | Improved alertness, relaxation, appetite, overall score, and general well-being (3 scales) |
| Smith et al., 1995 (cited in | 19 F | DB | 26 ±1 yr | 200 mg | G115 | 8 wk | NS for POMS and PANAS (psychological tests) and RPE |
| Sorensen et al., 1996 | 112 Healthy volunteers | R, DB, PC | >40 yr | 400 mg | G115 | 8-9 wk | Faster reaction times, better abstract thinking; NS for memory, concentration, well-being |
| Ziemba et al., 1999 | 15 Soccer players | DB | 19.07±0.62 yr | 350 mg | Ginseng preparation | 6 wk | Improved psychomotor performance during bicycle ergometer exercise without affecting exercise capacity |
| Kennedy et al., 2001 | 40 | R, DB, PC, CO | Young | 200, 400, and 600 mg | G115 | 7 d | Significant improvement in “quality of memory” and the associated “secondary memory” factor at all-time points following 400 mg of ginseng. Both the 200 and 600 mg doses were associated with a significant decrement of the “speed of attention” factor at later testing times only |
| Lee et al., 2008 | 97 | # | Alzheimer’s disease patients | 4.5 g/d | 12 wk | ||
| Reay et al., 2010 | 30 | R, DB, PC, CO | Healthy young adults (22.87±4.01) | 200 and 400 mg | G115 | 8 d | No evidence of additional benefits, or attenuation of acute effects following repeated ingestion of G115 |
| Heo et al., 2011 | 61 | # | Alzheimer ‘s disease patients 50-80 yr | 4.5, 9 g | Korean red ginseng | 96 wk | Improvement of cognitive deficit in Alzheimer ‘s disease patients |
| Yeo et al., 2012 | 15 M | R, DB, PC | Healthy young adults | 4.5 g | Korean red ginseng | 2 wk | Decreased latency in event-related potential test associated with improved cognitive function |
| Scholey et al., 2010 | 32 | R, DB, PC, CO | Healthy young adults | 100, 200, 400 mg | Cereboost ( | Acute administration | This study has identified robust working memory enhancement following administration of Cereboost |
#, data not listed or unavailable; CO, crossover; DB, double-blind; DMAE, dimethylaminoethanol; F, female; FSH, follicle stimulating hormone; GRS, ginseng-rhizome saponin; LH, luteinizing hormone; M, male; NC, not controlled; PANAS, positive and negative affect schedule; PC, placebo-controlled; POMS, profile of mood survey; R, randomized; RER, respiratory exchange ratio; RPE, ratings of perceived exertion; SB, single-blind; VE, expiratory ventilation.